FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma By Ogkologos - August 8, 2025 636 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LINKER-MM1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer January 7, 2026 Adding Autologous Stem-Cell Transplantation to Triplet Treatment, Followed by Lenalidomide Maintenance... July 27, 2022 Young Breast Cancer Survivors Without a Germline Pathogenic Variant Have a... April 23, 2024 Sisters on Opposite Sides of the Country Diagnosed with Breast Cancer... December 16, 2020 Load more HOT NEWS Safety and Preliminary Signs of Activity of OMO-103, a MYC Inhibitor,... Weekend in New England Five Questions With…Amber. Boy Asks Mom Fighting Cancer To Take Off Her Turban So...
